Sep 30, 2024 | Homepage News, News, Uncategorized
We’re back at it! PRF is thrilled to announce the start of a new Progeria clinical trial with a new drug called Progerinin. PRF will help fund and coordinate this trial to determine whether a new drug, called Progerinin, plus the life-extending Progeria drug...
Jul 24, 2024 | Homepage News, News, Uncategorized
In an article published today in the New York Times, PRF Medical Director Dr. Leslie Gordon and colleagues shared the phenomenal story of scientific collaborations that led to recent breakthroughs in genetic editing in Progeria. Partnerships with PRF’s long-time...
May 4, 2024 | Homepage News, News, Uncategorized
Effective Friday, May 3rd, 2024, Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd, has acquired global rights to lonafarnib (Zokinvy) from Eiger BioPharmaceuticals (Eiger). Zokinvy® is provided to...
Jan 5, 2024 | Homepage News, News, Uncategorized
We’re thrilled to share that PRF has been awarded – for the 10th consecutive year – the highest 4-star Charity Navigator rating! Charity Navigator is the top evaluator of U.S.-based nonprofits, and this coveted 4-star rating is awarded to fewer than 5% of the...
Oct 23, 2023 | Homepage News, News, Uncategorized
In partnership with Sciensus, The Progeria Research Foundation (PRF) is officially launching Progeria Connect to our full global community of families. We created this platform to help our small but diverse community make personal connections, have access to the...
